Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Future 3-5Y Total Revenue Growth Rate : N/A (As of Jun. 02, 2025)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Hunan Er-Kang Pharmaceutical Co's Future 3-5Y Total Revenue Growth Rate is N/A.

Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's Future 3-5Y Total Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hunan Er-Kang Pharmaceutical Co's Future 3-5Y Total Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's Future 3-5Y Total Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Hunan Er-Kang Pharmaceutical Co Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hunan Er-Kang Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Future 3-5Y Total Revenue Growth Rate

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Executives

Shuai Fang Wen	Director
Wang Jun Wen	Independent director
Zuo Tian Fang	Independent director
Qi Yang	Supervisors
Li Yi Guo	Supervisors
Chen Wen Xian	Supervisors
Wang Xiang Feng	Directors, executives
Liu Ai Jun	Directors, executives
Luo Lang	Directors, executives
Fan Yi	Securities Affairs Representative
Yang Hai Ming	Directors, executives
Shuai You Wen	Director
Shuai Rui Wen	Director
Gao Zhen Ya	Executives
Cao Zai Yun	Director

Hunan Er-Kang Pharmaceutical Co Headlines

No Headlines